Answers are grounded in this paper and cite their sources.
Purpose of review Studies have shown that megakaryopoiesis has expanded beyond the traditional thrombopoietin-driven pathway, revealing a complex developmental state and local context that, together, determine megakaryocyte (MK) maturation and platelet production. As understanding of this field grows, so does its impact on platelet-associated disease. This review outlines some emerging regulators of MK development and platelet biogenesis, culminating with their relevance to advancing in vitro platelet production. Recent findings Newly identified regulators have linked MK maturation to its microenvironment through mechanosensitive ion channels and integrins as well as to its metabolic state through redox balance, lipid remodeling, and mitochondrial function. Additionally, transcriptional, posttranscriptional, and inflammatory factors contribute significantly to MK development. In platelet biogenesis, studies continue the ongoing debate over pulmonary contributions while defining new cytoskeletal and metabolic regulators of proplatelet formation. Efforts to generate platelets in vitro have also increased with development of systems utilizing induced pluripotent stem cells, bioreactors, and molecular signals but remain limited by inefficient generation of activatable platelets. Summary Megakaryopoiesis and thrombopoiesis are context-dependent processes that are influenced by microenvironmental, metabolic, transcriptional, and inflammatory factors. Defining these networks advances potential therapeutic targets for platelet disorders and development of scalable donor-independent platelet generation in vitro.
No takes yet. Share an insight, caveat, or question.
Lu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: